



## Five Prime Therapeutics to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology

September 26, 2018

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep. 26, 2018-- [Five Prime Therapeutics, Inc.](#) (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology, Oct. 3, 2018, at 10:30 am ET.

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company's website at <http://investor.fiveprime.com/events.cfm>. Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.

### About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and the focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit [www.fiveprime.com](http://www.fiveprime.com) or follow us on [LinkedIn](#), [Twitter](#) and [Facebook](#)

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180926005865/en/>

Source: Five Prime Therapeutics, Inc.

Five Prime Therapeutics, Inc.  
Heather Rowe, 415-365-5737  
Senior Director, Investor Relations and Corporate Communications  
[heather.rowe@fiveprime.com](mailto:heather.rowe@fiveprime.com)